North America Antimicrobial Resistance Surveillance Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)
North America Antimicrobial Resistance Surveillance Market: by Type (Phenotypic Methods, Genotypic Methods, Microbial Culture, Rapid Diagnostic Testing, Data Analytics Platforms, Laboratory Information Management Systems), Application (Hospital, Pharmacy, Diagnostic Laboratories, Research Institutes, Government & Public Health Agencies, Veterinary Settings), Distribution Channels (Direct Sales, Distributors, Online Sales, Retail Pharmacies, Wholesalers, Others), Technology (Automated Susceptibility Testing, PCR-based Detection, Next-Generation Sequencing, Mass Spectrometry, Microarray, Whole Genome Sequencing), Organization Size (Small, Medium, Large) and By North America Historical & Forecast Period (2020-2035) Comprehensive Study 2025
Last Updated: 31-07-2025 | Format: PDF | Report ID:20296 | Author: Manisha C
North America Antimicrobial Resistance Surveillance Market Outlook 2025-2035
The North America Antimicrobial Resistance (AMR) Surveillance Market is projected to witness significant expansion between 2025 and 2035, propelled by escalating concerns regarding antimicrobial resistance and increasing investments in healthcare infrastructure. The market encompasses advanced diagnostic tools, surveillance platforms, and robust data management technologies, catering to hospitals, research institutes, and public health agencies. The adoption of automated susceptibility testing, PCR-based detection, next-generation sequencing (NGS), and whole genome sequencing (WGS) is accelerating, aiming to deliver rapid, reliable detection and containment of resistant organisms. Key companies are intensifying R&D and strategic collaborations to deliver state-of-the-art surveillance solutions. With heightened awareness toward AMR, expanded regulatory support, and advances in laboratory information systems, the region is poised for dynamic market growth, anchored by the U.S., Canada, and Mexico.
Latest Market Dynamics
Key Drivers
Rising Incidence of Antimicrobial Resistance: Increasing prevalence of multidrug-resistant infections is boosting demand for effective surveillance solutions. For example, Thermo Fisher Scientific has intensified investments in rapid testing kits following the surge of healthcare-acquired resistance in 2024.
Government Initiatives and Funding: Public health programs and significant funding for AMR detection and reporting are vital. In 2024, the U.S. CDC expanded collaborations with Roche Diagnostics to strengthen nationwide AMR surveillance infrastructure.
Key Trends
Integration of AI and Big Data Analytics: Adoption of artificial intelligence for real-time data analysis is gaining traction for pattern recognition. bioMérieux introduced enhanced machine learning algorithms in its surveillance portfolio in early 2024.
Growth of Rapid Diagnostic Technologies: Market shift toward point-of-care and near-patient solutions. Beckman Coulter, Inc. launched an automated platform for rapid susceptibility reporting in September 2024.
Key Opportunities
Expanding Cloud-Based Data Solutions: Growing interest in scalable, interoperable cloud infrastructure for surveillance. Siemens Healthineers announced cross-platform cloud enhancements for AMR data integration in October 2024.
Demand from Veterinary and Environmental Health Segments: Rising focus on 'One Health' initiatives creates market space beyond hospitals. Danaher Corporation extended its AMR analytics tools for veterinary diagnostics in July 2024.
Key Challenges
Standardization and Data Interoperability: Variability in data formats and protocols hampers cross-institutional monitoring. OpGen’s attempts to harmonize AMR reporting standards across North American labs highlighted ongoing technical hurdles in 2024.
Limited Lab Capacity in Rural Areas: Infrastructural gaps persist in remote regions, limiting surveillance coverage. Accelerate Diagnostics reported implementation challenges for its rapid platforms in smaller rural facilities mid-2024.
Key Restraints
High Implementation and Maintenance Costs: Advanced surveillance systems require substantial upfront capital. Illumina's WGS platforms, while highly accurate, can be cost-prohibitive for smaller organizations as per their 2024 report.
Complex Regulatory Compliance: Changing policies and privacy concerns delay solution deployment. Abbott Laboratories (Alere) navigated extensive regulatory review in Canada before launching new molecular surveillance kits in August 2024.
North America Antimicrobial Resistance Surveillance Market Share by Type (2025)
Rapid Diagnostic Testing leads the North America AMR surveillance market by type in 2025, reflecting the region's increasing demand for real-time, point-of-care infection detection. Automated susceptibility testing and genotypic methods are also significant, with hospitals and labs prioritizing technologies that deliver actionable results quickly and efficiently. The market's strong focus on speed and accuracy, coupled with rising threat of resistant pathogens, is driving the adoption of these advanced diagnostic types across clinical and research settings.
North America Antimicrobial Resistance Surveillance Market Share by Application (2025)
Hospitals dominate the application segment in the North America AMR surveillance market for 2025, accounting for the largest share due to their critical role in infection detection and management. Diagnostic laboratories and government/public health agencies are also vital contributors, reflecting ongoing investments in surveillance infrastructure and integration of advanced diagnostic platforms to manage antimicrobial-resistant infections at both the institutional and population levels.
North America Antimicrobial Resistance Surveillance Market Revenue (USD Million), 2020-2035
The market is projected to grow steadily, rising from USD 1,320 Million in 2020 to USD 3,890 Million by 2035. Government actions, advanced diagnostics, and expanded data analytics capacity are expected to fuel this growth. Key developments in rapid tests, genome sequencing, and public health investments are anticipated to further accelerate market value over the forecast period.
North America Antimicrobial Resistance Surveillance Market YOY Growth (%), 2020-2035
Year-over-year growth for the North America AMR surveillance market remains above 7% from 2025-2030, peaking at 8.1% in 2027 before moderating to 6.5% by 2035 as the market matures. Rollouts of next-generation solutions, regulatory mandates, and heightened public awareness are driving sustained double-digit surges in the early forecast years, with a gradual stabilization expected by the end of the period.
North America Antimicrobial Resistance Surveillance Market by Region Share (%) 2025
The United States commands the majority of the North America AMR surveillance market with 69% share, benefiting from its large healthcare infrastructure and ongoing government initiatives. Canada and Mexico follow with 19% and 12%, respectively, as these countries ramp up investments in national AMR surveillance and integrate modern diagnostic platforms into clinical and public health settings.
North America Antimicrobial Resistance Surveillance Market Players Share (%) 2025
Becton, Dickinson and Company holds the largest share at 15%, driven by its broad diagnostic product portfolio and extensive client network. Thermo Fisher Scientific and bioMérieux SA follow with 13% and 11%, respectively, buoyed by continued innovation and targeted partnerships. The competitive landscape remains dynamic with ongoing product launches and technology integration.
North America Antimicrobial Resistance Surveillance Market Buyers Share (%) 2025
Healthcare providers represent the largest group of buyers at 45%, reflecting hospitals’ and clinics’ prioritization of robust AMR surveillance for patient safety. Government & public health agencies acquire a 33% share due to national level surveillance initiatives, with research and diagnostic laboratories contributing 22% as they continue to expand testing and reporting capacities.
Study Coverage
Metrics
Details
Years
2020-2035
Base Year
2025
Market Size
2070
Regions
United States, Canada, Mexico
Segments
Phenotypic Methods, Genotypic Methods, Microbial Culture, Rapid Diagnostic Testing, Data Analytics Platforms, Laboratory Information Management Systems, Hospital, Pharmacy, Diagnostic Laboratories, Research Institutes, Government & Public Health Agencies, Veterinary Settings, Direct Sales, Distributors, Online Sales, Retail Pharmacies, Wholesalers, Automated Susceptibility Testing, PCR-based Detection, Next-Generation Sequencing, Mass Spectrometry, Microarray, Whole Genome Sequencing, Small, Medium, Large
August 2024: Abbott Laboratories receives Health Canada approval for a new molecular AMR surveillance panel, expanding lab-based detection for emerging pathogens.
September 2024: Beckman Coulter, Inc. launches an AI-driven rapid susceptibility platform for hospital laboratories, targeting turnaround improvements.
October 2024: Siemens Healthineers rolls out enhanced cloud-enabled AMR data integration across North America for multi-institutional real-time surveillance.
November 2024: Thermo Fisher Scientific collaborates with CDC to bolster U.S. public health agency capacity for rapid resistance detection and multi-site data harmonization.
July 2024: Danaher Corporation extends its AMR analytics solutions to include veterinary diagnostic networks in the U.S. and Canada under a 'One Health' initiative.
Frequently Asked Questions
About the Author
Manisha C
Lead Industry Analyst
Manisha C is a Lead Industry Analyst specializing in market research, industry analysis, and business consulting across Healthcare. Manisha C brings a commercially grounded perspective to sectors shaped by changing demand, innovation, and competitive dynamics, helping turn complex market trends into clear strategic insights for business decision-makers. With 10+ years of experience across research, analytics, and strategic advisory roles, Manisha C has helped organizations translate data into actionable growth strategies.
